In vivo monitoring of intranuclear p27kip1 protein expression in breast cancer cells during trastuzumab (Herceptin) therapy

Nuclear Medicine and Biology

Volumn 36, Issue 7, 2009, Pages 811-819

  Cornelissen, Bart ^a,c,d   Kersemans, Veerle ^a,c   McLarty, Kristin ^a,c   Tran, Lara ^c   Vallis, Katherine A ^d   Reilly, Raymond M ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Herceptin; Nuclear, p27kip1; Radioimmunoconjugates; Tat

Indexed keywords

ANTIBODY CONJUGATE; CARBOHYDRATE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1B ANTIBODY TAT PEPTIDE PENTETATE INDIUM IN 111; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G TAT IN 111; INDIUM 111; PENTETATE INDIUM IN 111; PENTETIC ACID; PEPTIDE; PERIODATE SODIUM; PROTEIN ANTIBODY; RADIOPHARMACEUTICAL AGENT; SCHIFF BASE; SODIUM CHLORIDE; TRASTUZUMAB; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CELL NUCLEUS; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EXPOSURE; DRUG RESPONSE; DRUG RETENTION; DRUG TRANSPORT; DRUG UPTAKE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MONITORING; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; PROTEIN INDUCTION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOCONJUGATES; INTRANUCLEAR SPACE; ISOTOPE LABELING; MICE; MOLECULAR SEQUENCE DATA; PENTETIC ACID; PEPTIDES; PROTEIN TRANSPORT; TIME FACTORS; TISSUE DISTRIBUTION; TREATMENT OUTCOME; UP-REGULATION;

EID: 69249205433     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.05.003     Document Type: Article

References (38)

1. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89 (1992) 4285-4289
2. Fornier M, Risio M, Van Poznak C, Seidman A. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Huntingt) 2002;16:1340-8, 51-2. [discussion 52, 55-8].
3. Hayes D.F., and Thor A.D. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 29 (2002) 231-245
4. Nahta R., and Esteva F.J. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 9 (2003) 5078-5084
5. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Sciences (New York) 235 (1987) 177-182
6. Jones A. Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?. Ann Oncol 14 (2003) 1697-1704
7. Harari D., and Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19 (2000) 6102-6114
8. Perez E.A., Suman V.J., Davidson N.E., Martino S., Kaufman P.A., Lingle W.L., et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24 (2006) 3032-3038
9. Albanell J., and Baselga J. Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J Natl Cancer Inst 93 (2001) 1830-1832
10. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
11. Vogel C.L., and Franco S.X. Clinical experience with trastuzumab (Herceptin). Breast J 9 (2003) 452-462
12. Lane H.A., Beuvink I., Motoyama A.B., Daly J.M., Neve R.M., and Hynes N.E. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 20 (2000) 3210-3223
13. Le X.F., McWatters A., Wiener J., Wu J.Y., Mills G.B., and Bast Jr. R.C. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res 6 (2000) 260-270
14. Yakes F.M., Chinratanalab W., Ritter C.A., King W., Seelig S., and Arteaga C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62 (2002) 4132-4141
15. Marches R., and Uhr J.W. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. Int J Cancer 112 (2004) 492-501
16. Nahta R., Takahashi T., Ueno N.T., Hung M.C., and Esteva F.J. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64 (2004) 3981-3986
17. Chu I.M., Hengst L., and Slingerland J.M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev 8 (2008) 253-267
18. Jeon J.H., Lee K.N., Hwang C.Y., Kwon K.S., You K.H., and Choi I. Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1. Cancer Res 65 (2005) 4485-4489
19. Costantini D.L., Hu M., and Reilly R.M. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm 23 (2008) 3-24
20. Kersemans V., Kersemans K., and Cornelissen B. Cell penetrating peptides for in vivo molecular imaging applications. Curr Pharm Des 14 (2008) 2415-2447
21. 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells. Nucl Med Biol 34 (2007) 37-46
22. Cornelissen B., McLarty K., Kersemans V., Scollard D.A., and Reilly R.M. Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection. Nucl Med Biol 35 (2008) 101-110
23. Hu M., Chen P., Wang J., Chan C., Scollard D.A., and Reilly R.M. Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer. Eur J Nucl Med Mol Imaging 33 (2006) 301-310
24. 123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1). Eur J Nucl Med Mol Imaging 34 (2007) 368-377
25. Hu M., Wang J., Chen P., and Reilly R.M. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1. Bioconjug Chem 17 (2006) 1280-1287
26. Fraker P.J., and Speck Jr. J.C. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 80 (1978) 849-857
27. Reed W., Florems V.A., Holm R., Hannisdal E., and Nesland J.M. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Virchows Arch 435 (1999) 116-124
28. Baekelandt M., Holm R., Trope C.G., Nesland J.M., and Kristensen G.B. Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin Cancer Res 5 (1999) 2848-2853
29. Costantini D.L., Chan C., Cai Z., Vallis K.A., and Reilly R.M. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 48 (2007) 1357-1368
30. Macara I.G. Transport into and out of the nucleus. Microbiol Mol Biol Rev 65 (2001) 570-594 table of contents
31. 111In-Labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1. Cancer Biother Radiopharm (2009) in press
32. Crombez L., Morris M.C., Deshayes S., Heitz F., and Divita G. Peptide-based nanoparticle for ex vivo and in vivo drug delivery. Current Pharma Des 14 (2008) 3656-3665
33. Pujals S., Fernandez-Carneado J., Lopez-Iglesias C., Kogan M.J., and Giralt E. Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim Biophys Acta 1758 (2006) 264-279
34. Legrier M.E., Oudard S., Judde J.G., Guyader C., de Pinieux G., Boye K., et al. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer 96 (2007) 269-276
35. Shrader M., Pino M.S., and McConkey D. ZD1839 (Iressa™) sensitivity is regulated through a p27-dependent mechanism in bladder cancer cells. AACR Meeting Abstracts (2005) 802
36. Shintani S., Li C., Mihara M., Yano J., Terakado N., Nakashiro K., et al. Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral oncology 40 (2004) 43-51
37. Hubina E., Nanzer A.M., Hanson M.R., Ciccarelli E., Losa M., Gaia D., et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 155 (2006) 371-379
38. Moore H.G., Shia J., Klimstra D.S., Ruo L., Mazumdar M., Schwartz G.K., et al. Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. Ann Surg Oncol 11 (2004) 955-961